Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (SHA:603811)
China flag China · Delayed Price · Currency is CNY
7.08
-0.11 (-1.53%)
Sep 10, 2026, 3:00 PM CST

SHA:603811 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
826.42810.87712.31669.61653.25693.45
Other Revenue
1.051.482.062.011.720.52
827.47812.35714.37671.63654.97693.96
Revenue Growth
6.74%13.72%6.36%2.54%-5.62%-8.46%
Cost of Revenue
246.76254.26225.17248.45217.8208.98
Gross Profit
580.71558.09489.2423.17437.17484.99
Selling, General & Admin
353.77326.72308.66246.92269.61280.27
Research & Development
48.0344.4447.0847.1444.339.72
Other Operating Expenses
13.9414.2812.347.467.7710.7
Operating Expenses
415.28385.07365.77302.46321.83331.21
Operating Income
165.44173.02123.43120.71115.34153.78
Interest Expense
-1.2-3.83-11.09-15.26-9.13-4.52
Interest & Investment Income
14.8333.3346.2867.1249.0831.87
Earnings From Equity Investments
9.49-----
Currency Exchange Gain (Loss)
-0.1-0.350.01-0.173.455.36
Other Non Operating Income (Expenses)
-0.380.22-0.07-0.31-0.11-0.99
EBT Excluding Unusual Items
188.07202.39158.56172.1158.62185.49
Impairment of Goodwill
-----2.42-2.92
Gain (Loss) on Sale of Investments
-----3.5510.69
Gain (Loss) on Sale of Assets
2221.0669.17-00.06-0.45
Asset Writedown
-9.08-4.77-24-7.47-0.41-0.5
Other Unusual Items
5.145.1614.49.4411.535.19
Pretax Income
206.12223.84218.13174.06163.84197.5
Income Tax Expense
26.8426.3817.3512.012.6626.27
Earnings From Continuing Operations
179.28197.47200.79162.05161.18171.23
Minority Interest in Earnings
-1.72-2.35-0.090.850.4-0.43
Net Income
177.56195.12200.7162.9161.58170.8
Net Income to Common
177.56195.12200.7162.9161.58170.8
Net Income Growth
-24.97%-2.78%23.21%0.81%-5.39%3.42%
Shares Outstanding (Basic)
449448461456462459
Shares Outstanding (Diluted)
449448461456462459
Shares Change
-0.87%-2.78%0.98%-1.19%0.66%0.59%
EPS (Basic)
0.400.440.440.360.350.37
EPS (Diluted)
0.400.440.440.360.350.37
EPS Growth
-24.31%0%22.01%2.03%-6.02%2.82%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
210.96234.99145.83123.93-86.929.38
Free Cash Flow Per Share
0.470.530.320.27-0.190.02
Dividend Per Share
0.2140.2140.1790.1430.1280.128
Dividend Growth
19.99%19.99%24.98%11.99%0%0%
Gross Margin
70.18%68.70%68.48%63.01%66.75%69.89%
Operating Margin
19.99%21.30%17.28%17.97%17.61%22.16%
Profit Margin
21.46%24.02%28.09%24.25%24.67%24.61%
Free Cash Flow Margin
25.49%28.93%20.41%18.45%-13.27%1.35%
EBITDA
259.52267.22218.56198.04176.89208.45
EBITDA Margin
31.36%32.90%30.59%29.49%27.01%30.04%
D&A For EBITDA
94.0994.295.1377.3261.5554.67
EBIT
165.44173.02123.43120.71115.34153.78
EBIT Margin
19.99%21.30%17.28%17.97%17.61%22.16%
Effective Tax Rate
13.02%11.78%7.95%6.90%1.62%13.30%
Revenue as Reported
827.47812.35714.37671.63654.97693.96
Advertising Expenses
-4.883.851.810.891.41